People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half, according to a new srudy.

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

An experimental drug can delay disability progression in advanced multiple sclerosis patients Tolebrutinib delayed disability ...